Teva Pharmaceutical (TEVA)
Raymond James analyst Elliot Wilbur maintained a Buy rating on Teva Pharmaceutical today. The company’s shares closed last Thursday at $11.53.
According to TipRanks.com, Wilbur ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -2.2% and a 44.8% success rate. Wilbur covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Amneal Pharmaceuticals, and Flexion Therapeutics.
Currently, the analyst consensus on Teva Pharmaceutical is a Moderate Buy with an average price target of $11.33.
Raymond James analyst Steven Seedhouse maintained a Buy rating on 89bio today. The company’s shares closed last Thursday at $20.06, close to its 52-week low of $16.85.
According to TipRanks.com, Seedhouse is a 4-star analyst with an average return of 7.9% and a 47.6% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Apellis Pharmaceuticals, and Alexion Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for 89bio with a $57.00 average price target, implying a 185.1% upside from current levels. In a report issued on May 31, Oppenheimer also assigned a Buy rating to the stock with a $60.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.